PT  - JOURNAL ARTICLE
AU  - Hall, V
AU  - Foulkes, S
AU  - Charlett, A
AU  - Atti, A
AU  - Monk, EJM
AU  - Simmons, R
AU  - Wellington, E
AU  - Cole, MJ
AU  - Saei, A
AU  - Oguti, B
AU  - Munro, K
AU  - Wallace, S
AU  - Kirwan, PD
AU  - Shrotri, M
AU  - Vusirikala, A
AU  - Rokadiya, S
AU  - Kall, M
AU  - Zambon, M
AU  - Ramsay, M
AU  - Brooks, T
AU - SIREN Study Group
AU  - Brown, CS
AU  - Chand, MA
AU  - Hopkins, S
TI  - Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020
AID  - 10.1101/2021.01.13.21249642
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.13.21249642
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249642.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249642.full
AB  - Background There is an urgent need to better understand whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection.Methods A large multi-centre prospective cohort was recruited from publicly funded hospital staff in the UK. Participants attended regular SARS-CoV-2 PCR and antibody testing (every 2-4 weeks) and completed fortnightly questionnaires on symptoms and exposures. At enrolment, participants were assigned to either the positive cohort (antibody positive or prior PCR/antibody test positive) or negative cohort (antibody negative, not previously known to be PCR/antibody positive). Potential reinfections were clinically reviewed and classified according to case definitions (confirmed, probable, possible (subdivided by symptom-status)) depending on hierarchy of evidence. Individuals in the primary infection were excluded from this analysis if infection was confirmed by antibody only. Reinfection rates in the positive cohort were compared against new PCR positives in the negative cohort using a mixed effective multivariable logistic regression analysis.Findings Between 18 June and 09 November 2020, 44 reinfections (2 probable, 42 possible) were detected in the baseline positive cohort of 6,614 participants, collectively contributing 1,339,078 days of follow-up. This compares with 318 new PCR positive infections and 94 antibody seroconversions in the negative cohort of 14,173 participants, contributing 1,868,646 days of follow-up. The incidence density per 100,000 person days between June and November 2020 was 3.3 reinfections in the positive cohort, compared with 22.4 new PCR confirmed infections in the negative cohort. The adjusted odds ratio was 0.17 for all reinfections (95% CI 0.13-0.24) compared to PCR confirmed primary infections. The median interval between primary infection and reinfection was over 160 days.Interpretation A prior history of SARS-CoV-2 infection was associated with an 83% lower risk of infection, with median protective effect observed five months following primary infection. This is the minimum likely effect as seroconversions were not included.Funding Department of Health and Social Care and Public Health England, with contributions from the Scottish, Welsh and Northern Irish governments.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN11041050Funding StatementThe study is funded by the UK Department of Health and Social Care and Public Health England with contributions from the Scottish, Welsh and Northern Irish governments Funding is also provided by the National Institute for Health Research as an Urgent Public Health Priority Study SH & VH are supported by the National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England NIHR200915.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Berkshire Research Ethics Committee Health Research Authority and Health and Care Research Approval Wales granted 22 May 2020. IRAS ID 284460All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to trusted researchers once the final study data is released.